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Abstract: New drug targets, markers of disease prognosis, and more efficient treatment options are
an unmet clinical need in breast cancer (BC). We have conducted a pilot study including patients
with luminal B stage breast cancer IIA–IIIB. The presence and frequency of various populations of
cancer stem cells (CSC) and somatic stem cells were assessed in the blood, breast tumor tissue, and
normal breast tissue. Our results suggest that patients with BC can be divided into two distinct
groups based on the frequency of aldehyde dehydrogenase positive cells (ALDH1+ cells) in the
blood (ALDH1hi and ALDH1low). In the ALDH1hi cells group, the tumor is dominated by epithelial
tumor cells CD44+CD24low, CD326+CD44+CD24−, and CD326−CD49f+, while in the ALDH1low
cells group, CSCs of mesenchymal origin and epithelial tumor cells (CD227+CD44+CD24− and
CD44+CD24−CD49f+) are predominant. In vitro CSCs of the ALDH1low cells group expressing
CD326 showed high resistance to cytostatics, CD227+ CSCs of the ALDH1hi cells group are sensitive
to cytostatics. Epithelial precursors of a healthy mammary gland were revealed in normal breast
tissue of patients with BC from both groups. The cells were associated with a positive effect of
chemotherapy and remission in BC patients. Thus, dynamic control of their presence in blood
and assessment of the sensitivity of CSCs to cytostatics in vitro can improve the effectiveness of
chemotherapy in BC.
Keywords: breast cancer; ALDH1; cancer stem cells; somatic stem cells; biomarkers
1. Introduction
Despite advances in diagnosis and treatment, breast cancer (BC) remains the lead-
ing cause of cancer death in women [1]. More than 1 million new cases of the disease
are registered annually [2]. After the diagnosis of BC, prognosis of complications and
the choice of optimal drug therapy are crucial [3]. Traditional prognostic measures are
the definition of metastases in the lymph nodes, the size of the tumor, and the type of
differentiation of tumor cells [1,3]. When searching for tumor markers, much attention
is paid to the tumor subtype, which is determined by the presence (or absence) of the
estrogen receptor (ER), progesterone receptor (PR), and the protein associated with the
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human epidermal growth factor receptor (HER2). In addition, the spectrum of prognostic
markers includes Ki-67, urokinase plasminogen activator, as well as plasminogen activator
inhibitors (PAI-1) [4]. Immunohistochemical assessment of these antigens was used as the
basis of diagnostic tests to determine the likelihood of disease recurrence (MammaPrint,
Prosigna, Oncotype DX, EndoPredict) [4]. However, the definition of these parameters is
insufficient for personalized treatment of patients with BC. In this regard, the search for
effective prognosis biomarkers and predictors of breast cancer therapy is relevant. For the
diagnosis and dynamic control of BC in the blood of patients, circulating tumor cells (CTC)
are determined [5]. However, breast cancer progression and metastasis are associated
with the presence of CSCs [5]. At the same time, breast tumor CSCs are an extremely
heterogeneous population [5]. Thus, we have hypothesized that CSCs can be used as an
early diagnostic marker and a basis of personalized treatment of BC.
According to modern concepts, inflammation is central to all types of cancer. It is
estimated that up to 20% of human cancers are initiated by the inflammatory process [6].
Inflammation initiates the tumor and promotes tumor growth thus playing a central
role at all stages of tumorigenesis, including progression, invasion, angiogenesis, and
metastasis [7–10].
In addition to inflammatory cells and proinflammatory cytokines, hematopoietic stem
and progenitor cells play an important role in the development of inflammation [11–13].
Hematopoietic stem cells (HSCs) can be present in the tumor stroma and differentiate into
stromal cells. Moreover, cells derived from hematopoietic stem cells play an important
role in the development of tumors [14]. However, this aspect is practically not considered
in clinical practice. HSCs act as a potential marker of inflammation and as a target for
anti-inflammatory therapy.
Other important players in tumor progression are endothelial progenitor cells [15].
Angiogenesis is observed at the preinvasive stage of the tumor process. This is indicated by
the formation of microvessels around the ducts, and the ducts are filled with proliferating
epithelial cells [16]. The process of neovascularization is activated simultaneously with the
growth of the tumor. New vessels not only help to cope with the growing metabolic needs
of the tumor, but also contribute to the spread of the tumor and metastasis. An unfavorable
prognosis of breast cancer correlates with increased microvascular density and a high level
of pro-angiogenic factors [17].
In this pilot study, we studied CSCs in breast cancer patients in order to find new
diagnostic biomarkers and predictors of complications. In addition, we have studied
somatic stem cells (SSC), hematopoietic stem cells, and CD309+ endothelial cells.
2. Materials and Methods
2.1. Patients
The study included 12 patients with IIA–IIIB (T1–4N0–3M0) breast cancer of the
luminal B and triple-negative molecular subtypes aged from 38 to 66 years (average age of
50.6 ± 3.02 years) who received treatment at the Cancer Research Institute of Tomsk NRMC
(Tomsk, Russia) from 2017–2018. Imaging of the primary breast lesion was performed by
mammography and ultrasonography. An immunohistochemical study was conducted to
determine the molecular subtype of the tumor before treatment. The luminal B subtype of
breast cancer was defined as ER+, PR+ or −, Ki67 > 30%, and all patients with the luminal
B subtype were HER2-negative. Some patients showed no expression of ER, PR, and HER2,
and they were classified as a triple-negative subtype. Histological diagnosis was confirmed
for all samples. Table S1 presents the clinical indicators of tumors in all 12 patients. Blood
samples from 10 healthy women of similar age were used as control.
This was a pilot investigation. Informed consent was obtained from all individual
participants included in the study. All procedures performed in the studies involving
human participants were in accordance with the ethical standards of the institutional
and/or national research committee and with the 1964 Helsinki declaration and its later
amendments or comparable ethical standards.
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2.2. Design of Investigation
Blood samples were obtained from patients one day before surgery (Figure 1). Breast
tumor and normal breast tissue were obtained from patients on the day of surgery.
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2.3. Isolation of Blood Mononuclear Cells
Lympholyte-H (CEDARLANE, Netherlands, Cedarlane Laboratories, Cat#CL5015)
protocol was used for the elimination of erythrocytes and dead cells from human blood
and receiving mononuclear cells.
2.4. Dissociation of Breast Cancer Cells and Mammary Tissue Cells
Human breast tumor and mammary tissue samples were dissociated overnight with colla-
genase/hyaluronidase enzymes (StemCell Technologies, Vancouver, Canada, BC, Cat#079128).
The human mammary organoids, obtained through differential centrifugation, were then dis-
sociated into a single cell suspension using trypsin/EDTA (StemCell Technologies, Vancouver,
Canada, Cat#07901), dispase (StemCell Technologies, Vancouver, Canada, Cat#07913) and
DNase (StemCell Technologies, Vancouver, Canada, Cat#07900) enzymes.
2.5. Flow Cytometry
Mononuclear cells from blood, human mammary tissue, and breast cancer tissue were
isolated as described above and the expression of surface markers on mononuclear cells
was analy ed using flow cytometry. Fc-receptors were blocked by pre-incubation of the
cells with unconjugated anti-CD16/CD32 antibodies for 10 min (eBioscience, San Diego,
CA, USA, Cat# 464219, 1/100 dilution) in 50 µL of 0.1% saponin (Sigma-Aldrich, St. Louis,
MO, USA, Cat# S4521) and 1% BSA (Sigma-Aldrich, St. Louis, MO, USA, Cat# A3059-100G)
in phosphate buffered saline (PBS) per t be. After the pre-incubation, cells susp nsions
were stained with fluorophore-conjugated monoclonal antibodies.
2.5.1. Measurement of ALDH Activity
An aldehyde dehydrogenase-based cell detection kit (StemCell Technologies, Vancou-
ver, BC, Canada, Cat#01700) was used to de ermine ALDH1 enzymatic activity the blood,
breast tumor, and normal breast tissue. Cells were suspended in aldefluor assay buffer
and incubated with the ALDH enzyme substrate, BODIPY-aminoacetaldehyde (BAAA),
for 40 min at 37 ◦C. As a control, cells were also treated with diethylaminobenzaldehyde
(DEAB), an inhibitor of ALDH enzyme activity. Fluorescence was determined using a BD
FACS Canto II flow cytometer and analyzed using FACSDiva software (BD Biosciences).
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2.5.2. Detection of Hemopoietic Stem Cells
A two-color research reagent CD45/CD34 (Becton Dickinson, San Jose, CA, USA, Cat#
341071) was used to determine the presence of HSCs. The reagent contains FITC-labeled
CD45, clone 2D1, and PE-labeled CD34, clone 8G12. We determined HSC according to the
ISHAGE protocol [18].
2.5.3. Detection of Cancer Stem Cells and Somatic Stem Cells
Cell suspensions were stained with fluorophore-conjugated monoclonal antibodies.
The following antibodies were used for cell surface staining of mononuclear cells de-
rived from blood and tumors of patients: PE-Cy7-conjugated anti-CD24, APC-conjugated
anti-CD44, APC-H7-conjugated anti-CD45, PE-conjugated anti-CD49f, FITC-conjugated
anti-CD227, PerCP-Cy5-conjugated anti-CD326 (EpCAM), and PE-conjugated anti-CD309
(all Becton Dickinson, San Jose, CA, USA). The following isotype control groups were
used: PerCPCy5.5 IgG1, APC IgG2b, APC-H7 IgG2b, PE IgG2a, FITC IgG1, and PE-Cy7
IgG1. All antibodies were titrated to determine their optimal staining concentration and
appropriate isotype controls were used. Labeled cells were washed thoroughly with 500 µL
of FACSFlow (Becton Dickenson, Franklin Lakes, NJ, USA, Cat# 342003).
All samples were run on a Becton Dickenson FACSCanto II flow cytometer. The
instrument was set up and standardized using BD Cytometer Setup and Tracking (CS&T)
procedures according to manufacturer specifications. Data were analyzed using FACSDiva
8.0 software.
2.6. Isolation of Breast Cancer Cells
The CD326+ and CD227+ cell fractions were isolated using the EasySep™ Human
CD326 (StemCell Technologies, Canada, Vancouver, Catalog #18356) or CD227 (StemCell
Technologies, Canada, Vancouver, Catalog #18359) positive selection kit according to the
technical protocol supplied by StemCell Technologies (StemCell Technologies, Canada,
Vancouver). For EasySep™ cell separation, the labeled cell suspension was placed in
the EasySep™ magnet for 5 min, and the cells that were not magnetically labeled were
discarded. Labeled cells were resuspended, and the separation was repeated a total of
6 times. The EasySep™ cell separation was evaluated by flow cytometry.
2.7. In Vitro Tumor Study
Figure 2 shows the experimental design of the in vitro investigation.
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cell counter and then seeded at densities of 5 × 105 cells/mL in low adherence 6-well plates.
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The cultures were maintained in Human EpiCult-C (StemCell Technologies, Vancouver,
Canada), supplemented with 5% fetal bovine serum (FBS, Sigma-Aldrich, St. Louis, MO,
USA) for 24 h, and then the medium was replaced with serum-free medium and maintained
for an additional 10 days. At the end of the assays, the colonies were counted under a
microscope. After 10 days, the medium was removed and the plates gently rinsed with PBS.
The cultured cells were then counted. The procedure was repeated three times. Sorted cells
were seeded and cultivated in MammoCultTM (StemCell Technologies, Vancouver, Canada,
Cat#05620) supplemented with 0.48 µg/mL freshly dissolved hydrocortisone (StemCell
Technologies, Vancouver, Canada, Cat#07904) and 4 µg/mL heparin (StemCell Technologies,
Vancouver, Canada, Cat#07980) and 10 ng/mL IL-6 (Sigma-Aldrich, St. Louis, MO, USA,
Cat# SRP3096) to induce greater numbers of mammospheres and tumorspheres, and the
cultures were maintained for an additional 7 to 10 days. At the end of the assay, cells were
assessed by flow cytometry and image processing of each well with Cytation™ 3.
CD227+- and CD326+-sorted cell populations were cultivated in the presence of
10 ng/mL cytostatics (docetaxel (Taxotere (T)) + adriamycin (A) + cyclophosphamide
(C), TAC). Levels of apoptosis were evaluated after 2 h culture using flow cytometry and
image processing of each well with Cytation™ 3.
In the next stage, we chose a patient with a high grade of malignancy and a high
level of ALDH1+ cells circulating in the blood. The patient received cycles of TAC-based
chemotherapy. We studied the dynamics of the count of tumor cells in the blood before
and after surgery, after courses of chemotherapy. Moreover, we studied in vitro culture
tumor cells isolated from breast tumor tissue of this patient with and without cytostatics.
For the in vitro study, cytostatics which the patient received were used. Figure 3 shows the
experimental design of these investigations in vitro.
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2.8. Imaging
Images of CD227+ and CD326+ cells were obtained using a Cytation 3 cell imaging
multimode reader (BioTek Instruments, Inc., Winooski, VT, USA) tuned to DAPI, GFP, and
Texas Red light cubes.
At the end of the incubation period, CD227+ and CD326+ were counter stained with
Hoechst 33342 (blue) for cell number measurements, or Annexin V-iFluor™ 350 Conjugate
and 7-AAD fluorescent probes for apoptosis/ necrosis assessments. Then, a Cytation 3
(magnification of 4× or 20×) was imaged, followed by cell analysis using Gen5™ data
analysis software (Bad Friedrichshall, Germany).
All collected images were pre-processed to align the background before applying
analytical methods. Cell analysis was performed on a blue channel to determine cell count
based on the number of Hoechst-stained nuclei. The default settings resulted in adequately
calculated data for further analysis.
2.9. Statistical Analysis
All statistical analyses were carried out by using SPSS statistical software (version 15.0,
SPSS Inc., Chicago, IL, USA). Statistical analysis was performed using the Mann–Whitney
U test. Additionally, p values < 0.05 were considered to indicate statistically significant
differences. All quantitative data presented are the mean value and standard error.
3. Results and Discussion
The ideal way to identify and track disease recurrence and/or progression in cancer
patients is through surrogate marker approaches that are minimally invasive, reliable, and
allow for longitudinal testing of accessible sample types, such as blood. At present, no
single molecular or cellular blood marker has been proven to have such properties in BC.
The most commonly used molecular markers are carcinoembryonic antigen or products
of the MUC-1 gene expressed by tumor cells [19]. The high heterogeneity of the CSC
phenotype in cancer was the reason for the study of various oncoantigens in our study.
When studying blood samples from patients with BC, we found an increase in the number
of tumor cells with overexpression of CD227 and CD326, as well as CSCs of mesenchymal
origin (CD44+CD24−) compared to the levels in healthy volunteers (Figure 4). Moreover,
we observed an increase in the HSCs and CD309+ endothelial cells in the blood relative
to healthy volunteers. In addition, in BC an increase in the number of ALDH1+ cells
circulating in the blood was observed.
Our results are consistent with the literature, which indicates a correlation between the
tumor progression and the number of HSCs and endothelial cells in the blood [15]. There-
fore, it is important to investigate the potential presence of HSC and endothelial cells in the
peripheral blood of patients with BC, in addition to the already known tumor markers.
The tumor fraction ALDH1 is widely used as a biomarker of metastatic activity and
a determinant of the clinical outcome of breast cancer [20]. The collection of material for
biopsy is a rather painful intervention. Notably, prognostic potential of ALDH1+ CTC in
patients with BC was suggested in the literature [20–22]. ALDH expression by circulating
tumor cells correlates with poor clinical outcome, metastatic progression, and the response
to therapy in patients with metastatic breast cancer [22]. Another study suggested that
ALDH1 expression in primary breast tumors correlates with the presence of CTCs and
clinical outcome in patients with non-metastatic disease [22]. Objectively, ALDH1+ cells
circulating in the blood can be used as diagnostic markers. In our study, we found that
patients with BC differed in the content of ALDH1+ cells in the blood. We identified a group
of patients with a significant number of ALDH1+ cells (≥0.9% of all isolated mononuclear
cells, group ALDH1hi cells) and a group of patients with a small number of ALDH1+ cells
(≤0.9% of all isolated mononuclear cells, group ALDH1low cells) (Figure 5). It is important
to note that the level of ALDH1+ cells in the tumor of patients of ALDH1hi cells group was
also higher than that of patients of the ALDH1low cells group.
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Figure 4. Characterization of epithelial tumor cells and tumor stem cells population, HSC (CD45+CD34+) and CD309+
endothelial cells isolated from blood of patients with BC and healthy volunteers. Cells were analyzed by flow cytometry
using antibodies for CD24, CD34, CD44, CD45, CD227, CD309, CD326, and ALDH1. We used the two-color research reagent
CD45/CD34 to determine HSC. We determined HSC according to ISHAGE protocol. (a) The level of epithelial tumor cells
(CD45−CD227+CD44+CD24−/low), tumor stem cells (CD44+CD24−), HSC (CD45+CD34+) and CD309+ endothelial cells
in the blood of patients with BC and healthy v lunteers; (b) phenotype establishment a d qualitative analysis of CD45
(APC-H7), CD227 (FITC), CD326 (PerCP-Cy5.5), CD24 (PE-Cy7), D44 (APC). * Differences are significant in comparison
with healthy volunteers (p < 0.05).
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Figure 5. Isolation f circulating ALDH1+ cells from the blood of BC pati nts. (a) The patients with BC were divided i to
two distinct groups bas on the level of aldehyde dehydrogenase positive cells (ALDH1+ cells) in th blood. (a) Aldefluor
FACS analysis of the BC patients with ≤0.9 % of all isolated mononuclear cells (ALDH1low); (b) Aldefluor FACS analysis of
the BC patients with ≥0.9 % of all isolated mononuclear cells (ALDH1hi); (c) the level of circulating ALDH1+ cells; (d) the
level of ALDH1+ cells in tumor. * Differences are significant in comparison with the ALDH1hi group (p < 0.05).
In BC, metastases in their development go through the mesenchymal and epithelial
phases of the metastatic cascade [22]. ALDH1 is involved in the epithelial and more
proliferative phase of metastatic tissue colonization. In this regard, the use of ALDH1 as
a key biomarker of the metastases risk may be more useful in the diagnosis of advanced
breast cancer (epithelial phase) [22]. In patients with an unexpanded disease, which is
characterized by an intravascular and more mesenchymal phase of the metastatic cascade,
the level of ALDH1 expression is s gnificantly reduced. We found confirmation of this
in the present study. According to our data, a patient of the ALDH1hi cells group had
metastases in the lungs.
When determining other antigens, we found intergroup differences in other CSCs. The
ALDH1hi cells group showed an increased number of epithelial tumor cells CD44+CD24low,
CD326+CD44+CD24−, and CD326–CD49f+ (Figure 6). At the same time, in the ALDH1low
cells group, the content of CSCs of mesenchymal origin (CD44+CD24−), epithelial tumor
cells (CD227+CD44+CD24− and CD44+CD24−CD49f+), HSCs, and CD309+ endothelial
cells in the tumor prevailed.
Despite the increas d level of ALDH1 in the patients with BC, we did not find an
increase in the numbers of HSC and CD309+ endothelial cell levels in the blood or tumor
tissue compared to patients with ALDH1low. It is known that endothelial cells play a
role in tumor progression by promoting the progression of avascular micrometastasis to
vascularized macrometastases [23]. HSCs play an important role in the development of
inflammation and tumor progression [14].
We suggest that patients with different levels of ALDH1 in the blood can suffer from
tumors at different stages. The populations of CSC, HSCs, and endothelial cells isolated in
this study can be used as markers for personalized tumor therapy, and disease prognosis.
Since we did observe group differences in the content of tumor CD326+CD44+CD24−
cells and CD227+CD44+CD24− cells from the tumor of patient A of the ALDH1hi cells
group and patient B of the ALDHlow cells group, we isolated CD326+ and CD227+ cells,
obtained primary cultures, and characterized them. At the same time, we evaluated the
effects of IL-6 (a factor that stimulates CSC [24]) and cytostatics proposed for chemotherapy
(CT) in vitro.
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Figure 6. Characterization of HSC, epithelial tumor cells and tumor stem cells population isolated from tumor of patients
with BC. Cells were analyzed by flow cytometry using antibodies for CD24, CD44, CD49f, CD227, CD326, and CD45/CD34
(for HSC). The patients with BC were divided into two distinct groups based on the level of aldehyde dehydrogenase
positive cells (ALDH1+ cells) in the blood (≥0.9% of all isolated mononuclear cells, ALDH1hi and ≤0.9% of all isolated
mononuclear cells, ALDH1low). * Differences are significant in comparison with the ALDH1hi group (p < 0.05).
CD227+ cells of patient B and CD326+ cells of patient A were investigated (Figure 7a).
We found that in patient B, the culture of CD227+cells was characterized by the absence
of cells in apoptosis, insignificant clonal activity (mammosphere) and an increase in cell
mass during the cultivation cycle (Figure 7d–f). In culture of CD227+ cells of patient B, IL-6
increased the frequency of mammosphere formation. After co-cultivation with cytostatics,
the proportion of apoptotic CD227+ cells was 70% (Figure 7b,c).
The culture of CD326+ cells of patient A withstood three passages and by the end
of the cultivation cycle its cell mass significantly increased. Moreover, the frequency of
mammosphere formation increased in the presence of IL-6 (Figure 7a). The activity of the
cells of patient A in culture was superior to those of patient B. On the other hand, patient
A’s CD326+ cells were resistant to cytostatics: the number of cells in apoptosis was 14%
versus 27% in patient B.
These data made it possible to suggest that when diagnosing breast cancer, it is
desirable to determine the level of ALDH1+ cells circulating in the blood and the ratio of
CD326+ and CD227+ tumor cells in the tumor. These cells can act as tumor progression
factors and inducers of metastases in all groups, regardless of ALDH1 expression. To
increase the effectiveness of chemotherapy, we suggest in vitro selection of cytostatics. This
approach can enhance effective patient care.
In the next stage, we studied the count of tumor cells in the blood before and af-
ter surgery, after courses of chemotherapy of the patient received cycles of TAC-based
chemotherapy (Figure 8a). We observed a decrease in the content of CD227+CD44+CD24−,
CD227+, and CD44+CD24low cells in the blood after surgery. However, we observed an
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increase in the content of these cell populations after courses of chemotherapy. We suggest
that changes in blood can be associated with the resistance of cancer cells to chemotherapy.
We studied in vitro cultured CSCs and tumor cells isolated from breast tumor tissue of this
patient with and without cytostatics (Figure 8b–d). We found no changes in the count of
dead tumor cells and apoptotic tumor cells. Moreover, no differences were observed in
the count of tumor cells (CD326−CD49+, CD326+CD227+, CD326+CD44+CD24−, CD227+,
CD227+CD44+CD24−) after a cycle of cultivation with cytostatics (TAC) treatment.
Thus, dynamic control of circulating CSCs of patients with BC makes it possible
to detect cells with the potential for tumor progression and metastasis in the blood. In
addition, in vitro assessment of the sensitivity of the CSC to the chemotherapy may allow
a quick correction of the patient’s treatment.
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CD326+-cell enriched environment after a cycle of cultivation a d IL-6 treatment (% of the initial cell content in each
population); (b) the count of tumor cells with apoptosis after a cycle of cultivation without cytostatic (1) and with cytostatics
(docetaxel (taxotere (T)), adriamycin (A) and cyclophosphamide (C)), (2) treatment in the CD326+ cell population of patient
A and CD227+ cell population of patient B; (c) 20× images of CD227+ and CD326+ cells stained with: Hoechst (blue) to
identify cell nuclei; annexin V (green); 7-AAD (red); (Hoechst + Annexin V + 7-AAD) composite image using all three colors.
Determination of the percentage of cells in apoptosis was made by the ratio of cells counted in green and red channel to total
cells counted using blue (DAPI) channel. All scale bars are 1000 µm; (d) the count of tumor cells (CD326−CD49+) after a cycle
of cultivation without cytostatic (1) and with cytostatics (docetaxel (taxotere (T)), adriamycin (A) and cyclophosphamide
(C)) (2) treatment in the CD326+ cell population of patient A and CD227+ cell population of patient B; (e) The count of
tumor cells (CD326+CD44+CD24−) after a cycle of cultivation without cytostatic (1) and with cytostatics (docetaxel (taxotere
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population of patient B; (f) the count of tumor cells (CD227+C 44+CD24−) after a cycle f cultivation without cytostatic
(1) and with cyt statics (docetaxel (taxotere (T)), adriamycin (A) and cyclophosphamide (C)) (2) treatment in the CD326+
cell population of patient A and CD227+ cell populati n of patient B.
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In conclusion, it should be noted that in the breast tissue adjacent to the tumor (normal
tissue) and tumor tissue of patients with BC, different populations of epithelial progenitor
cells of a healthy mammary gland were revealed (Figure 9). We did not find significant
differences in their content between the patients of the ALDH1hi and ALDH1low groups.
In all groups, cells were associated with a positive effect of chemotherapy and remission
of patients with BC. Thus, targeting epithelium and endothelium regeneration of the
mammary gland might be beneficial and prevent tumors. However, our study has some
limitations. Since we performed a short-term single-center study, it has a relatively small
sample size, which diminishes the likelihood of generalization. To assess their applicability
to a larger population, the results presented here need further validation using multi-center
cohorts with large numbers of patients.
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Figure 9. Characterization of bipotent precursors of breast cells (CD326lowCD49fhiCD227+) (a,e), basal tissue-specific stem
cells of the mammary gland (CD326hiCD49fhi) (b,f), precursors of luminal cells (CD326lowCD49flowCD227+) (c,g), and
precursors of myoepithelial cells (CD326lowCD49f+) (d,h) isolated from the breast tissue adjacent to the tumor (normal
tissue) (a–d) and tumor tissue (e–h) of patients with BC of the ALDH1hi and ALDH1low groups. Cells were analyzed
by flow cytometry using antibodies for CD49f, CD227, and CD326. * Differences are significant in comparison with the
ALDH1hi group (p < 0.05).
4. Conclusions
Patients with IIA–IIIB (T1-4N0-3M0), triple negative BC, and HER+ BC, are divided
into a group with a significant number of ALDH1+ cells and a group with a small num-
ber of ALDH1+ cells in the blood and tumors. The composition of tumor CSCs and
their activity in patients of the ALDH1hi cells group and the ALDH1low cell group differ.
ALDH1 expression level and ratio of tumor cells CD44+CD24low, CD326+CD44+CD24−,
CD326−CD49f+, CSC of mesenchymal origin (CD44+CD24−) and epithelial tumor cells
(CD227+CD44+CD24− and CD44+CD24−CD49f+), HSC, and CD309+ endothelial cells in
Biomedicines 2021, 9, 1223 13 of 14
tumors can act as personalized diagnostic markers, predictors of complications and the
effectiveness of breast cancer treatment in further research. Moreover, the dynamic control
in the blood and assessment of the sensitivity of CSCs to cytostatics in vitro can improve
the effectiveness of chemotherapy in BC.
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